Skip to content

ARA-290 vs TB-500

Updated 9 sources

Key differences

  1. 1ARA-290 targets nerve repair and neuropathic pain with Phase 2 human data. TB-500 is framed as general tissue repair with mostly preclinical data.

Side by side

Facts from each record, in the same words as their own pages.
ARA-290 and TB-500 side by side
ARA-290TB-500
Category
  • Healing & recovery, Immune
  • Healing & recovery
Evidence
  • Limited human data
  • Animal data only
FDA status
  • FDA 503A Category 3Regulatory
  • Not FDA approvedRegulatory
WADA
  • Prohibited
  • Prohibited
Half-life
  • About 2 minutes in plasma; the biological effects last much longer. Plasma enzymes trim it quickly.Clinical study
  • Not established in humans for the fragment. Full-length thymosin beta-4 by IV lasted longer at higher doses; one guide cites 0.5 to 2.1 hours.Clinical study
Routes
  • Subcutaneous injection, Intravenous (IV)
  • Subcutaneous injection, Intramuscular injection
Forms
  • Vial (powder)
  • Vial (powder)
Reported doses
  • 1 to 8 mg (subcutaneous injection)
  • 2 mg (intravenous (iv))
  • 1 to 5 mg (subcutaneous injection)
  • 2 to 2.5 mg (intramuscular injection)
  • 500 to 1,000 mcg (subcutaneous injection)
Most cited frequency
  • Once daily
  • Twice weekly
Vial sizes
  • 10 mg, 16 mg, 5 mg, 50 mgCompetitor guide
  • 2 mg, 5 mg, 10 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 C, out of light.Competitor guide
  • Fridge at 2 to 8 C, dark, never frozen.Competitor guide
Protocols on file
  • 10
  • 19

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Competitor guide1

  1. ARA-290 peptide protocol guidepeptidedosingprotocols.com · checked Oct 24, 2026